Skip to Main Content

View Public Comments for Aprepitant for Chemotherapy-Induced Emesis

Use the browser below to select the Comment Period for which you would like to view the comments for the selected document. You can use the alphabetical links above the results table to jump to comments submitted by a commenter whose last name starts with that letter. Select the ‘Expand All Comments’ link to view all the full comments, and click the ‘Collapse All Comments’ link to view only the abstract for all comments. Select the ‘More’ link in the Comment to view the full text of the specific comment in a new window.
The first (earliest) set of comments are displayed by default in the Public Comment Results section. To view additional Comment Periods, use the radio button options and select the "Submit" button.
An asterisk (*) indicates a required field.

      Select one period.


[38 Comments]
Page 1 of 2
FirstPrev12NextLast
First character of titleCommenterComment Information
B
Berger, Michael Organization: The James Cancer Hospital
Date: 01/09/2005
Comment:

This is an outstanding decision which will immensely benefit a subpopulation of patients who have failed standard anti-emetics. Our outpatient oncology clinic has struggled to obtain / provide this drug for our patients up until now. Hopefully, More opens in new window

B
Browne, Roy Date: 01/27/2005
Comment:

Apprepitant should be covered by medicare as many
patients will benefit from using it. It really
helps patients who are receiving highly
emetogenic More opens in new window

C
Chesbro, Byron Title: M.D.
Organization: Texas Oncology
Date: 01/14/2005
Comment:

As a medical oncologist, I applaud the decision
to provide coverage for the use of aprepitant in
those patients receiving highly or moderately
emetogenic regimens who experience delayed nausea
and vomiting. The treatment of More opens in new window

D
DARNELL, ROBERT Title: Nursing Supervisor
Organization: The Cleo Craig Memorial Cancer and Research Clinic
Date: 01/26/2005
Comment:

Emend is a wonderful drug and should be approved
by Medicare. However, you need to allow the
patient to take the IV form of a 5ht-3 because
if they don't have prescription coverage, and
have to pay 20% out of pocket for the oral More opens in new window

E
Escudier, Susan Date: 01/14/2005
Comment:

This is an important drug for the cancer patient
and has made a huge difference in quality of
life, ability to work, etc by reducing nausea and
vomiting after More opens in new window

G
Gershon, Barry Title: Director, Public Policy and Advocacy
Organization: GlaxoSmithKline
Date: 02/04/2005
Comment:

GlaxoSmithKline appreciates the opportunity to comment on the recent National Coverage Analysis (CAG-00248N) that would extend Medicare Part B coverage to aprepitant, an oral anti-emetic under certain circumstances. The product would only More opens in new window

H
Hoverman, Russell Title: Vice President
Organization: Texas Oncology, P.A.
Date: 02/03/2005
Comment:

We have added aprepitant to our antiemetic
guidelines which I shall submit as a separate
attachment. Its use is reasonable in high risk
patients or in those who have had difficulty with
platinum containing More opens in new window

H
Howard, Kay Title: Pharmacist
Organization: University Physicians (Upstate Medical University Hospital)
Date: 01/27/2005
Comment:

I am a Pharmacist in the outpatient Oncology
setting. I feel that it is important that Emend
(Aprepitant) be allowed for any oncology patient
that is currently or about to begin treatments
for Moderate to Highly emetogenic More opens in new window

H
Hyland, Sharon Title: Nurse Practitioner
Organization: James P Wilmot Cancer Center, Rochester, NY
Date: 01/25/2005
Comment:

As a Nurse Practitioner working in Breast Service I would recommend consideration of giving Emend with Dexamethasone on the first course of Adriamycin/Cytoxan because of the high incidence of debilitating delayed nausea and More opens in new window

J
Johnson RN, CNS, AOCN, Sandy Title: RN, CNS, AOCN
Organization: Coborn Cancer Center
Date: 01/13/2005
Comment:

I work within a busy cancer center. For the past
25 years I have been an oncology nurse. I have
witnessed many improvements in the way we treat
patients and in our ability to extend life for
cancer patients. One of the most More opens in new window

J
Johnson, M.D., David Title: President
Organization: American Society of Clinical Oncology
Date: 01/27/2005
Comment:

On behalf of its more than 20,000 members involved in cancer treatment and research, the American Society of Clinical Oncology (ASCO) commends the Centers for Medicare & Medicaid Services (CMS) for its ongoing efforts to modernize More opens in new window

K
kedziera, pamela Title: Clinical Manager
Organization: Fox Chase Cancer Center
Date: 01/21/2005
Comment:

Nausea and vomiting are always unpleasant. For
an individual with cancer who is struggling to
maintain their physical health as well as their
quality of life, the control of these symptoms is
critical. Aprepitant has More opens in new window

k
Kozlovski, PharmD, Anna Title: Oncology Clinical Pharmacist
Organization: Our Lady of Mercy Medical Center Onc/Hem Deptartment
Date: 01/14/2005
Comment:

Emend is an anti-emetic that has been very effective for patients getting highly emetogenic chemo regimens as well as patients that failed on standard therapy. We've been using Emend throughout last year and have seen tremedous results. Like More opens in new window

L
Lindley, Celeste Date: 01/14/2005
Comment:

I strongly support the decision to reimburse for Emend however patents should not have to fail prior antiemetic therapy in order to receive Emend. The literature clearly shows that cycle 1 protection is critical to subseqent CINV control. Please More opens in new window

M
McCarthy, James Title: Oncology Pharmacy Manager
Organization: Montefiore Medical Center
Date: 01/31/2005
Comment:

Aprepitant is more effective in the treatment of
CINV for highly emetogenic drugs, when used in
combination with other anti-emetic drugs. CMS
coverage of the drug will improve patient
outcomes by reducing the incidence of nausea More opens in new window

M
McClay, Edward Title: Director, San Diego Melanoma Research Center
Organization: San Diego Cancer Center
Date: 01/21/2005
Comment:

I would respectfully submit that the current
requirement for patients receiving Level 4/5
chemotherapy to fail anti-emetic medication
before we can prescribe Aprepitant incurs an
undo burden on patients. These regimens by More opens in new window

M
mcewuen, sylvia Title: Clinical Trials Nurse/Data Manager
Organization: Clinical Trials Research Unit
Date: 01/14/2005
Comment:

This drug should be approved by Medicare for use
in the first cycle of any chemotherapy known to
be highly likely to cause nausea/vomiting.
Patients should not have to endure
nausea/vomiting because they are waiting to see More opens in new window

M
Mehta, Marjaana Title: Oncology Nurse Practitioner
Organization: University Medical Center of Southern Nevada
Date: 01/28/2005
Comment:

I have seen wonderful results with Emend in my
patients receiving chemotherapy. I absolutely
support reimbursement for Emend by Medicare.
However, I do not think that such restrictions
should be placed. I disagree with More opens in new window

M
Miller, Bonnie Title: R,N,
Date: 01/23/2005
Comment:

I strongly believe that Medicare coverage should
not be limited to patients who have failed on
other antiemetic regimens and Medicare coverage
should follow national guidelines for antiemetic
therapy. More opens in new window

M
Mills, Cheryl Organization: St. Luke's Regional Medical Center
Date: 01/13/2005
Comment:

I am a Nurse Practitoner working in a busy
outptient oncology clinic. I often see patients
who have failed standard antiemetic regimins and
thus become volume depleted. Usually this then
involves a few days of IV hydration and More opens in new window

M
Morton, RN, OCN, Paula Title: RN, OCN
Organization: South Florida Center for Gynecologic Oncology
Date: 01/11/2005
Comment:

Our practice regularly uses aprepitant in
combination with other pre- and post-chemotherapy
medications for the PREVENTION of CINV for highly
and moderately ematogenic chemotherapy drugs. In
almost all of our patients (98%), More opens in new window

O
Oholendt, Michael Title: Clinical Pharmacy Specialist, Heme/Onc/BMT
Organization: Center for Cell and Gene Therapy, Baylor College of Medicine/ Methodist Hospital
Date: 02/01/2005
Comment:

Aprepitant quietly crept into the oncology
armamentarium for CINV and proven to be rather
understated. CINV is a serious issue for
patients undergoing emetogenic chemotherapy.
Kudos to CMS for agreeing to cover the oral More opens in new window

O
Oster, Martin Title: Associate Professor of Clinical Medicine
Organization: Columbia University Medical Center
Date: 01/20/2005
Comment:

As a busy clinical oncologist since 1976, I have seen a continued improvement in controlling and minimizing chemotherapy-induced emesis over the past 28 years. Emend has been a major step forward in dealing with this difficult aspect of oncology More opens in new window

O
Ostrow, Dr. Stanley Date: 01/18/2005
Comment:

Emend is highly effective and is very necessary
for patients getting Emetogenic chemo (a
medication that induces nausea). Emend should
be used first line to prevent people from
getting sick instead of waiting until after. More opens in new window

P
Panackova, Silvie Date: 01/12/2005
Comment:

Emend has been a breakthrough medication for many
patients going through highly emetogenic
chemotherapy regimens. I have seen many personal
testimonials from patients who have greatly
benefited from this drug. Medicare patients More opens in new window

Page 1 of 2
FirstPrev12NextLast
34